December 12, 2025 8:04am

A Humpty-Dumpty: Capricor Therapeutics (CAPR) closed down -$1.49 after Wednesday’s +$1.29, Tuesday’s -$1.18 and Monday’s +$1.67 with a negative -$0.01 or -0.04% pre-open? Less conviction!

Pre-open Signals: 5 Positive and 4 Negative Indications

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

TGIF

Thursday’s RMi Closing Bell: Troubled waters … https://www.regmedinvestors.com/articles/14226

https://www.regmedinvestors.com/articles/13812

 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Friday: The pre-open Dow futures are UP +0.17% or (+85 points), the S&P futures are DOWN -0.17% or (-11 points) and the Nasdaq futures are DOWN -0.57% or (-147 points)

  • Stock futures were mixed Friday, 12/12
  • European markets rose
  • Asia Pacific markets traded higher

Economic data reporting: Wholesale inventories and 2 Fed presidents Philadelphia’s Anna Paulson and Cleveland Beth Hammack speak

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Thursday: The Dow closed UP +646.26 points or +1.34%, the S&P closed UP +14.32 points or +0.21% while the Nasdaq closed DOWN -60.30 points or -0.26%
  • Wednesday: The Dow closed UP +497.46 points or +1.05%, the S&P closed UP +46.17 points or +0.67% while the Nasdaq closed UP +77.669 points or +0.33%
  • Tuesday: The Dow closed DOWN -179.03 points or -0.38%, the S&P closed DOWN -6 points or -0.09% while the Nasdaq closed UP +30.582 points or +0.13%
  • Monday: The Dow closed DOWN -215.67 points or -0.45%, the S&P closed DOWN -23.89 points or -0.35% while the Nasdaq closed DOWN -32.224 points or -0.14%
  • Last week: The S&P 500 is up +0.3%, the Dow +0.5% and the Nasdaq is up +0.9%.
  • The previous week: The S&P 500 increased +4%. the Dow +3% and the Nasdaq jumped 1%.
  • November ended: the S&P 500 and Dow were slightly higher, as the Nasdaq fell 2%,

 

Q4 – December, 4 positive and 4 negative closes

  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Pre-open, I take the top 10 and bottom 10 of the previous session's closes to measure the potential of the morning’s possibles ... examine the aftermarket against the pre-market indications

  • IQVIA Holdings (IQV) closed up +$3.06 after Wednesday’s +$5.19 after Tuesday’s -$5.51 after Monday’s -$2.28 with a positive +1.01 or +0.45% pre-open
  • Moderna (MRNA +$0.60 after Wednesday’s +$0.79 after Tuesday’s +$0.27 with a negative -$0.17 or -0.57% pre-open
  • Ionis Pharmaceuticals (IONS) closed up +$0.51 after Wednesday’s +$0.23 after Tuesday’s -$2.65 after Monday’s -$0.17 with a positive +$0.15 or +0.19% pre-open
  • CRISPR Therapeutics (CRSP) closed up +$0.50 after Wednesday’s +$0.55 with a positive +$0.15 or +0.26% pre-open
  • Supernus Therapeutics (SUPN) closed up +$0.35 after Wednesday’s +$0.74 after Tuesday’s -$1.74 after Monday’s +$1.48 with a negative -$0.16 or -0.34% pre-open
  • BioNTech (BNTX) closed up +$0.26 after Wednesday’s -$0.11 with a positive +$0.32 or +0.33% pre-open
  • WVE Life Sciences (WVE) closed down -$3.48 after Wednesday’s -$1.08 after Tuesday’s +$2.79 after Monday’s +$11.03 with a positive +$0.42 or +2.51% pre-open
  • Vericel (VCEL) closed down -$0.25 after Wednesday’s -$0.74, Tuesday’s +$1.08 and Monday’s +$1.07 with a negative -$0.11 or -0.39% pre-open

 

The BOTTOM LINE: Still feeling the what … anxiety with a small dose/feeling of optimism!

Welcome to my world of defining the “grey’ in our universe!

  • The stock market rally continues to show strength and breadth, with the key indexes nearing record highs and a variety of leading stocks flashing buy signals but, I say a downdraft!
  • With a downside end-of-month and year rotation and rebalance, In the last of December and 2025, it means investors have to be careful of slippage targets.

This week:

  • 12/11 – Thursday closed negative with 18 positive, 19 negative and 3 flats
  • 12/10 – Wednesday closed positive with 24 positive, 12 negative and 4 flats
  • 12/9 - Tuesday closed negative with 10 positive, 27 negative and 3 flats
  • 12/8 - Monday closed positive with 22 positive, 16 negative and 2 flat

Last week:

  • 12/5 – Friday closed negative with 13 positive, 26 negative and 1 flat
  • 12/4 – Thursday closed positive with 26 positive, 12 negative and 2 flats
  • 12/3 – Wednesday closed positive with 35 positive, 4 negative and 1 flat
  • 12/2 - Tuesday closed negative with 10 positive, 29 negative and 1 flat
  • 12/1 – Monday closed negative with 5 positive, 31 negative and 0 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.